Wikipedia
Acalabrutinib
Acalabrutinib (rINN, ACP-196) is an experimental anti-cancer drug and a 2nd generation BTK inhibitor developed by Acerta Pharma.
It is designed to be more selective (fewer side-effects) than ibrutinib.
it is in late stage clinical trials for relapsed chronic lymphocytic leukemia. Interim results are encouraging : 95% overall response rate.
It is also in another 20 clinical trials (alone and in combination) for various cancers.